WEKO3
アイテム
Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
http://hdl.handle.net/2298/26382
http://hdl.handle.net/2298/26382810349a1-8335-41e0-b111-2878401cdc0a
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
K.Hirashima.mTOR_Figure Legends_.pdf (50.2 kB)
|
|
|
|
20120104Figure.pdf (972.6 kB)
|
|
|
|
K.Hirashima.mTOR_Table 1_.pdf (15.3 kB)
|
|
|
|
British J. Cancer.106.5.876-882.pdf (170.1 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2013-01-16 | |||||
| タイトル | ||||||
| タイトル | Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | everolimus, RAD001, mTOR, oesophageal squamous cell carcinoma, proliferation | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
Hirashima, Kotaro
× Hirashima, Kotaro× 馬場, 祥史× 渡邊, 雅之× Karashima, Ryu-ichi× Sato, Nobutaka× Imamura, Yu× Nagai, Yohei× Hayashi, Naoko× Iyama, Ken-ichi× Baba, Hideo |
|||||
| 別言語の著者 |
平島, 浩太郎
× 平島, 浩太郎× 馬場, 祥史× 渡邊, 雅之× 辛島, 龍一× 佐藤, 伸隆× 今村, 裕× 長井, 洋平× 林, 尚子× 猪山, 賢一× 馬場, 秀夫 |
|||||
| 内容記述 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Background: The mammalian target of rapamycin (mTOR) protein is important for cellular growth and homeostasis. The presence and prognostic significance of inappropriate mTOR activation have been reported for several cancers. Mammalian target of rapamycin inhibitors, such as everolimus (RAD001), are in development and show promise as anti-cancer drugs; however, the therapeutic effect of everolimus on oesophageal squamous cell carcinoma (OSCC) remains unknown. Methods: Phosphorylation of mTOR (p-mTOR) was evaluated in 167 resected OSCC tumours and 5 OSCC cell lines. The effects of everolimus on the OSCC cell lines TE4 and TE11 in vitro and alone or in combination with cisplatin on tumour growth in vivo were evaluated. Results: Mammalian target of rapamycin phosphorylation was detected in 116 tumours (69.5%) and all the 5 OSCC cell lines. Everolimus suppressed p-mTOR downstream pathways, inhibited proliferation and invasion, and induced apoptosis in both TE4 and TE11 cells. In a mouse xenograft model established with TE4 and TE11 cells, everolimus alone or in combination with cisplatin inhibited tumour growth. Conclusion: The mTOR pathway was aberrantly activated in most OSCC tumours. Everolimus had a therapeutic effect both as a single agent and in combination with cisplatin. Everolimus could be a useful anti-cancer drug for patients with OSCC. |
|||||
| 書誌情報 |
British Journal of Cancer 巻 106, 号 5, p. 876-882, 発行年 2012-02-28 |
|||||
| ISSN | ||||||
| 収録物識別子 | 00070920 | |||||
| PubMed番号 | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 22333597 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 関連識別子 | 10.1038/bjc.2012.36 | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| 形態 | ||||||
| 値 | 170101 bytes | |||||
| 形態 | ||||||
| 値 | 15251 bytes | |||||
| 形態 | ||||||
| 値 | 972604 bytes | |||||
| 形態 | ||||||
| 値 | 50226 bytes | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
| 日本十進分類法 | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 493 | |||||
| 出版者 | ||||||
| 出版者 | Nature Publishing Group | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 論文(Article) | |||||
| 資源タイプ・ローカル | ||||||
| 値 | 雑誌掲載論文 | |||||
| 資源タイプ・NII | ||||||
| 値 | Journal Article | |||||
| 資源タイプ・DCMI | ||||||
| 値 | text | |||||
| 資源タイプ・ローカル表示コード | ||||||
| 値 | 01 | |||||
| URL | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | http://www.nature.com/bjc/journal/v106/n5/abs/bjc201236a.html | |||||
